Aug. 22, 2024 — The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such ...

Unfortunately, this shirt comes in the smallest size range of any of our picks; the largest size offered is a men’s XL. Its cotton is discernibly different. Made from 100% North Carolina cotton ...

After speaking to footwear experts and testing multiple pairs, we named the Amberjack Original the most comfortable dress shoes for men: They’re designed with supportive heat-activated midsoles ...

and product designers who have spent hours working out in gyms and fitness classes — these are the best all-around men’s workout shoes. I’ve noted where each of these shoes excels most ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). The GoResp ...

Sandals Resorts International (SRI), the Caribbean’s leading hotel chain, on Thursday described as “unfortunate and misguided” allegations made against the company by a former senior ...

Everyone knows there’s a special kind of bliss that comes from breezing through the day in a pair of super comfortable shoes — including Anne Hathaway. Last week the Oscar-winning actress ...

Navy clearance divers have among the highest suicide rates in the defence force, and an ABC investigation has spoken to more than a dozen who believe they have brain injuries related to blast ...

Teva and partner Alvotech’s hopes of launching their biosimilar of AbbVie’s high-potency formulation of big-selling immunology drug Humira have been dashed, after the FDA turned down their ...

London: EU antitrust regulators are set to fine world No. 1 generic drugmaker Teva in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone ...